Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Cabinet Nod to Rs 330...

    Cabinet Nod to Rs 330 crore loan to 3 pharma PSUs for clearing staff liabilities

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-07-19T15:03:37+05:30  |  Updated On 16 Aug 2021 5:36 PM IST
    Cabinet Nod to Rs 330 crore loan to 3 pharma PSUs for clearing staff liabilities

    NEW DELHI: The Union Cabinet Wednesday approved loans of Rs 330.35 crore to three state-owned pharma companies to help them clear employees' liabilities, and announced setting up of a ministerial panel to decide on the closure or sale of four PSUs. The Cabinet, chaired by Prime Minister Narendra Modi, took the decision to provide budgetary support as loan to the tune of Rs 330.35 crore for meeting the employees' liabilities of Indian Drugs & Pharmaceuticals Ltd (IDPL), Rajasthan Drugs and Pharmaceuticals Ltd (RDPL) and Hindustan Antibiotics Ltd (HAL).


    Also Read: USFDA finds adulteration, violations of CGMP regulations at Strides Pharma Puducherry plant


    "Budgetary support of Rs 330.35 crore would help in disbursing the unpaid salaries and providing support for VRS of employees of IDPL, RDPL and HAL. The decision would mitigate sufferings of more than 1,000 employees of these PSUs," an official statement said.


    Of the Rs 330.35 crore, Rs 158.35 crore will be utilised to clear unpaid salary and Rs 172 crore for meeting the VRS liability.


    The cabinet also approved constitution of a committee of ministers for taking all decisions pertaining to closure/ strategic sale of four public sector undertakings, including the sale of assets and clearance of outstanding liabilities, it added.


    "Setting up of a Committee of Ministers would expedite in process of implementation of the earlier Cabinet decision dated December 28, 2016 for closure of IDPL and RDPL and strategic sale of HAL and BCPL (Bengal Chemicals & Pharmaceuticals Ltd)," the statement said.


    In 2016, the cabinet had decided to sell surplus land of HAL, IDPL, RDPL and BCPL through open competitive bidding to government agencies and clear the outstanding liabilities from the sale proceeds, it added.


    "It was decided that after meeting the liabilities, IDPL and RDPL would be closed and HAL and BCPL put up for strategic sale," the statement said.


    The government said that efforts were made to sell surplus land, but it could not find buyers, despite issuing tenders more than once.


    Meanwhile, the Department of Public Enterprises (DPE) has issued revised guidelines on June 14, 2018 in respect of disposal of land of the PSUs, it added.


    Also Read: Despite legal hassles, JnJ beats profit estimates on pharma strength


    "As funds could not be generated through sale of surplus land, the employees in few of the PSUs (HAL and RDPL) could not be paid salaries and VRS scheme floated. As such, it was decided to dispose of the land as per revised DPE's guidelines and seek up-front budgetary support for meeting employees' liabilities," the statement said.

    BCPLBengal Chemicals & Pharmaceuticals Ltdcabinetclearing staffemployeeshalHindustan Antibiotics LtdIDPLIndian Drugs & Pharmaceuticals LtdloanNarendra Modipharmapharma companypharma loanpharma newspsuRajasthan Drugs and Pharmaceuticals LtdRDPLUnion Cabinetvrs liability
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok